Genprex, Inc. (GNPX)

3.40
NASDAQ
Prev Close 3.82
Day Low/High 3.22 / 3.88
52 Wk Low/High 1.95 / 7.72
Exchange NASDAQ
Shares Outstanding 43.28B
Market Cap 165.32M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Inspect the Fingerprints on the Genprex Offering, Before Making a Move

Inspect the Fingerprints on the Genprex Offering, Before Making a Move

Let's get out the magnifying glass and examine GNPX's selling of 4 million shares and the hit it took on Tuesday.

Let's Look at the Big Picture of Genprex

Let's Look at the Big Picture of Genprex

After GNPX's private placement on Tuesday, I spoke with the CEO, Rodney Varner. Here's what I found out and what my views are on the developer of cancer and diabetes therapies.

We May Have a Trade in Front of Us Right Here for Genprex

We May Have a Trade in Front of Us Right Here for Genprex

The options don't give a ton of choices, but I like the buy-write.

Let the Pols Trade Barbs, We'll Trade Stocks ... and Look to the Futures

Let the Pols Trade Barbs, We'll Trade Stocks ... and Look to the Futures

As the pundits decide who won, I'm looking at these biotech names with a focus on Myovant Sciences.

Immatics Is a Biotech Where Patient Investors Could Be Handsomely Rewarded

Immatics Is a Biotech Where Patient Investors Could Be Handsomely Rewarded

2021 will be a big year, upside is at least twice the current valuation, and downside is limited to 10% from current levels.

This Biotech Appears to Have the Right Formula for Investors

This Biotech Appears to Have the Right Formula for Investors

After reviewing the rally, let's zero in on one biotech name, Genprex, and where it appears to be going.

I Like the Technical Setup in Genprex

I Like the Technical Setup in Genprex

Overall I believe GNPX shapes up well in the biotech space.

Now's the Time for Companies to Mix It Up

Now's the Time for Companies to Mix It Up

Firms should be using their high stock price to grab other businesses to expand, so they're ready when things return to normal.

Sometimes, Stories Do Come True

Sometimes, Stories Do Come True

Two names I've talked about, AYRO and GNPX, saw their stories get closer to reality on Tuesday.

Upwork Shares Are Breaking Out Higher Today

Upwork Shares Are Breaking Out Higher Today

The initial target here is $16 with a secondary target of $17.50 on this breakout, with a time frame of a month or less.

This Mistake Could Pay You Dearly

This Mistake Could Pay You Dearly

A desperate deal by Genprex could spell opportunity for investors. Here's how.

Genprex Is Soaring - And There's a One Word Reason Why

Genprex Is Soaring - And There's a One Word Reason Why

The small biotech's market cap sits at $125 million, the low end of what I believe is fair.

Genprex Has the Right Formula for a Trade

Genprex Has the Right Formula for a Trade

I've followed this name before it went public, and it's got some potentially promising treatments in its pipeline.

Those Golden Rule

Those Golden Rule

If you want a perfect example of this, look at two recent capital raises: one from Tesla and one from Genprex over the past week.

Genprex: The Bad and the Good of Capital Raises

Genprex: The Bad and the Good of Capital Raises

For those who love a roll of the dice, GNPX may be worth a closer look.

How to Buy the Right Broken Stocks

How to Buy the Right Broken Stocks

I hold two broken stocks at the moment: GreenSky and Genprex.

Innoviva Is Attractive Play in Biotech

Innoviva Is Attractive Play in Biotech

Strong balance sheet and royalties are big positives for Innoviva.

How to Play Molina Health

How to Play Molina Health

Shares are finally reversing post-earnings slide in February.